acute myeloid leukemia with inv3(p21;q26.2) or t(3;3)(p21;q26.2)

Acute myeloid leukemia with inv(3)(q21;q26.2) or t(3;3)(q21;q26.2) is a subtype of acute myeloid leukemia that involves a specific genetic abnormality. In this condition, myeloid cells (a type of blood cell) multiply abnormally in the bone marrow and blood, which can also affect other tissues in rare cases. Bone marrow examinations often reveal small, hypolobated megakaryocytes (platelet precursor cells) along with signs of multilineage dysplasia. This means that several blood cell types may be affected, contributing to a range of symptoms and complications.

People with this condition may experience symptoms related to the production of abnormal blood cells. Common signs include an increase in white blood cells (leukocytosis), low red blood cell counts (anemia), and variable levels of platelets. They might also experience fatigue, bleeding, bruising, frequent infections, and bone pain. Some individuals can have symptoms from involvement outside the bone marrow, such as swollen gums (gingivitis) or an enlarged spleen (splenomegaly).

This form of acute myeloid leukemia is characterized by a distinct genetic change in the chromosomes. The disorder involves an inversion or a translocation between specific parts of chromosome 3 (inv(3)(q21;q26.2) or t(3;3)(q21;q26.2)). This genetic abnormality leads to the clonal proliferation of abnormal myeloid blasts in the bone marrow and blood.

Treatment for this condition can be challenging due to high resistance to conventional chemotherapy. Specific treatment options and detailed management approaches are not fully outlined in the provided information.

The outlook for individuals with this type of acute myeloid leukemia can be affected by its resistance to standard chemotherapy. Information about long-term outcomes and quality of life considerations is limited and may vary by individual.

Information about current research and future directions is currently limited for this condition.